Oaktree Acquisition Corp. III Life Sciences (OACCU) stock analysis
Financial Services · Shell Companies
From the 10-K filed 2026-03-26
How it makes money
It currently earns non-operating income through interest on $191,990,290 held in trust while seeking a healthcare target valued up to $1.5 billion.
It has no active operations or commercial revenue. Its primary financial activity is generating interest income from the proceeds of its initial public offering, which are held in a trust account.
Its ultimate profit model depends on completing a merger with a biopharmaceutical, medical device, or healthcare services company. It focuses on targets in North America and Europe with enterprise values between $500 million and $1.5 billion, seeking entities that will benefit from a public currency and Oaktree's long-term sponsorship.
What growth costs
It spends $25,000 monthly on administrative fees and draws from $1,434,965 in non-trust cash to evaluate potential biopharmaceutical and medical device targets.
Maintaining its search for an acquisition requires funding for due diligence, travel, and legal reporting. As of late 2025, it held $1,434,965 outside its trust account specifically for these operational needs.
It pays its sponsor $25,000 per month for office space and administrative support. If these funds are exhausted before an acquisition, it depends on its sponsor or management team to provide loans, which may be converted into private placement units at $10.00 each.
What could damage it
If it fails to consummate a business combination by October 25, 2026, it must liquidate the trust account and its warrants will expire worthless.
The company operates under a strict 24-month deadline from its initial public offering. If it does not close an acquisition by October 25, 2026, it is required to cease operations, redeem public shares at their pro rata value, and dissolve.
This mandatory liquidation would result in the complete loss of value for warrant holders, as warrants do not participate in trust distributions. Furthermore, high redemption rates by public shareholders could deplete the trust, potentially making the company an unattractive partner for high-quality targets.
About Oaktree Acquisition Corp. III Life Sciences
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was founded in 1995 and is headquartered in Los Angeles, California.